Premium
Robot‐assisted radical cystectomy: intermediate survival results at a mean follow‐up of 25 months
Author(s) -
Martin Aaron D.,
Nunez Rafael N.,
Pacelli Anna,
Woods Michael E.,
Davis Rodney,
Thomas Raju,
Andrews Paul E.,
Castle Erik P.
Publication year - 2010
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2009.09042.x
Subject(s) - cystectomy , medicine , lymph node , bladder cancer , surgery , survival rate , lymph , pathological , urology , cancer , pathology
Study Type – Therapy (case series)
Level of Evidence 4 OBJECTIVE To assess the overall and disease‐specific survival rates of patients undergoing robot‐assisted radical cystectomy (RARC) compared with historical open cystectomy. PATIENTS AND METHODS Survival, pathological and demographic data were collected on all patients undergoing RARC for bladder cancer from both Tulane University Medical Center and Mayo Clinic Arizona. Of a total of 80 RARCs we only included those with a follow‐up of ≥6 months from surgery. Survival curves were compared with those from historical series of open cystectomy. RESULTS Of the 80 patients 59 were identified as having a follow‐up of ≥6 months from the date of surgery. The mean (range) follow‐up was 25 (6–49) months. Overall survival rates at 12 and 36 months were 82% and 69%, respectively, and disease‐specific survival rates were 82% and 72% at 12 and 36 months, respectively. These results are comparable to survival rates from open cystectomy. As expected, patients with lymph node‐positive disease fared worse than those with lymph node‐negative disease. Patients with extravesical lymph node‐negative disease (pT3, pT4) fared worse than patients with organ‐confined lymph node‐negative disease. Also, patients with lymph node‐positive disease fared worse than those with extravesical lymph node‐negative disease, which is consistent with historical results of open cystectomy. CONCLUSIONS RARC has a comparable survival rate to open cystectomy in the intermediate follow‐up. Further study with a longer follow‐up and more patients is necessary to determine any long‐term survival benefits.